New Issue: Credit Suisse sells $1.61 million autocallable securities on biotech ETF

By Wendy Van Sickle

Columbus, Ohio, Dec. 29 – Credit Suisse AG, London Branch, priced $1.61 million of 0% autocallable securities due Dec. 29, 2020 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will be called at par plus a premium of 12% a year if the fund closes at or above its initial level on either of two annual observation dates.

If the return of the fund is at least equal to its initial level, the payout at maturity will be par plus 36%. Investors will be exposed to any decline of the fund.

Credit Suisse Securities (USA) LLC is the agent.

Issuer:	Credit Suisse AG, London Branch
Issue:	Autocallable securities
Underlying ETF:	SPDR S&P Biotech ETF
Amount:	$1,605,000
Maturity:	Dec. 29, 2020
Coupon:	0%
Price:	Par
Payout at maturity:	If return of fund is at least equal to initial level, par plus 36%, investors will be exposed to any decline in fund
Call:	At par plus 12% per year if fund closes at or above initial level either of two annual observation dates
Initial price:	$85.88
Pricing date:	Dec. 27
Settlement date:	Dec. 29
Agents:	Credit Suisse Securities (USA) LLC
Fees:	3.2%
Cusip:	22550BTF0

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.